We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

2 hedge funds and large institutions have $1.13M invested in Aptevo Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

17% less capital invested

Capital invested by funds: $1.36M → $1.13M (-$234K)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$822K
2
SM
Sabby Management
Florida
+$822K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$18.7K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$17.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$440K +$822K +2 New
AC
2
Armistice Capital
New York
$408K +$822K +2 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$73K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$58K – – –
SSA
5
Schonfeld Strategic Advisors
New York
$47.1K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$24.9K – – –
CF
7
Cantor Fitzgerald
New York
$18.6K – – –
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$16K – – –
BlackRock
9
BlackRock
New York
$15.7K – – –
Northern Trust
10
Northern Trust
Illinois
$4.66K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$4.45K – – –
Morgan Stanley
12
Morgan Stanley
New York
$3.63K – – –
Franklin Resources
13
Franklin Resources
California
$3.63K – – –
State Street
14
State Street
Massachusetts
$3.61K – – –
DWA
15
Divergent Wealth Advisors
Utah
$3.3K – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$629 – – –
Wells Fargo
17
Wells Fargo
California
$515 – – –
Fifth Third Bancorp
18
Fifth Third Bancorp
Ohio
$96 – – –
PNC Financial Services Group
19
PNC Financial Services Group
Pennsylvania
$47 – – –
TC
20
Truvestments Capital
Florida
$31 – – –
UBS Group
21
UBS Group
Switzerland
$28 – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$9 – – –
AF
23
Allworth Financial
California
$6 – – –
EARNEST Partners
24
EARNEST Partners
Georgia
$5 – – –
Citigroup
25
Citigroup
New York
$3 – – –
1
2

APVO Hedge Fund Activity: Q3 2023 in Review

2 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q3 2023, worth a combined $1.13M — down 17% from $1.36M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new APVO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $822K. The largest seller was Citadel Advisors, cutting an estimated $18.7K.

  • 2 institutional investors held Aptevo Therapeutics (APVO) as of Q3 2023, up from 0 in Q2 2023.
  • Funds reported $1.13M of Aptevo Therapeutics stock for Q3 2023, down 17% quarter-over-quarter.
  • 2 funds opened new Aptevo Therapeutics positions in Q3 2023 and 0 closed out, a net change of +2 holders.
  • The largest Aptevo Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $822K added.
  • The largest Aptevo Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $18.7K sold.

Based on aggregated 13F filings for Q3 2023.